PerkinElmer to Acquire Nexcelom Bioscience in Strategic Expansion

PerkinElmer, a leading global developer of innovative healthcare solutions, has announced its strategic agreement to acquire Nexcelom Bioscience, a Massachusetts-based cell counting and analysis company. This acquisition is set to enhance PerkinElmer’s capabilities in cell and gene therapy, as well as biologics manufacturing. Nexcelom, known for its complementary technologies, brings significant expertise to PerkinElmer’s preclinical portfolio, aiming to accelerate the development and market delivery of novel therapies. 

PerkinElmer, headquartered in Waltham, Massachusetts, serves customers across 190 countries and is a prominent component of the S&P 500 index with 2020 revenues of approximately $3.8 billion. The acquisition of Nexcelom, expected to generate around $40 million in revenue in 2021, aligns with PerkinElmer’s mission to innovate for a healthier world. By integrating Nexcelom’s robust cell analysis capabilities, PerkinElmer will further streamline workflows for their clients, which include academic, governmental, and biopharmaceutical organizations. This move underscores PerkinElmer’s commitment to addressing significant scientific and healthcare challenges by providing precise and timely solutions.

The PerkinElmer-Nexcelom acquisition highlights a significant expansion in cell biology leadership, poised to impact advancements in drug discovery and development. By leveraging Nexcelom’s expertise, PerkinElmer aims to enhance its services in crucial healthcare sectors, ultimately supporting the acceleration of bringing breakthrough therapies to market. This strategic decision strengthens PerkinElmer’s role in fostering innovation and improving global health outcomes.

For the latest updates and in-depth insights into the world of Analytical Science, including breakthrough treatments, industry trends, and regulatory news, contact Adam Tiberius today!